These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20937175)

  • 21. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High incidence of intolerance to tuberculosis chemoprophylaxis.
    Haroon M; Martin U; Devlin J
    Rheumatol Int; 2012 Jan; 32(1):33-7. PubMed ID: 20658233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C; Hutton B; Yazdi F; Wolfe D; Hamel C; Quach P; Skidmore B; Moher D; Alvarez GG
    BMC Infect Dis; 2017 Apr; 17(1):265. PubMed ID: 28399802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
    Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
    Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
    Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review.
    Abad CLR; Deziel PJ; Razonable RR
    Transpl Infect Dis; 2019 Dec; 21(6):e13178. PubMed ID: 31541575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.
    Noh CS; Kim HI; Choi H; Kim Y; Kim CH; Choi JH; Hyun IG; Baek MS
    Respir Med; 2019 Oct; 157():52-58. PubMed ID: 31522030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort.
    Chiang LY; Baumann B; Romanowski K; Kumar D; Campbell JR; Djurdjev O; Morshed M; Sekirov I; Cook VJ; Levin A; Johnston JC
    Am J Kidney Dis; 2021 May; 77(5):696-703. PubMed ID: 32818551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
    Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
    Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
    Sekaggya-Wiltshire C; von Braun A; Scherrer AU; Manabe YC; Buzibye A; Muller D; Ledergerber B; Gutteck U; Corti N; Kambugu A; Byakika-Kibwika P; Lamorde M; Castelnuovo B; Fehr J; Kamya MR
    J Antimicrob Chemother; 2017 Apr; 72(4):1172-1177. PubMed ID: 28108678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
    Fountain FF; Tolley E; Chrisman CR; Self TH
    Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
    Bray MG; Poulain C; Dougados M; Gossec L
    Joint Bone Spine; 2010 Mar; 77(2):135-41. PubMed ID: 20097592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy.
    Kaptan Y; Suner A; Taş MN; Oksel F; Aksu K; Sayiner A
    Clin Rheumatol; 2021 Sep; 40(9):3783-3788. PubMed ID: 33745083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM
    Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION].
    Ito K
    Kekkaku; 2016 Sep; 91(9):607-616. PubMed ID: 30646464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.